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SUMMARY
SETTING—A large randomized controlled trial recently showed that for treating latent 
tuberculous infection (LTBI) in persons at high risk of progression to tuberculosis (TB) disease, a 
12-dose regimen of weekly rifapentine plus isoniazid (3HP) administered as directly observed 
treatment (DOT) can be as effective as 9 months of daily self-administered isoniazid (9H).
OBJECTIVES—To assess the cost-effectiveness of 3HP compared to 9H.
DESIGN—A computational model was designed to simulate individuals with LTBI treated with 
9H or 3HP. Costs and health outcomes were estimated to determine the incremental costs per 
active TB case prevented and per quality-adjusted life year (QALY) gained by 3HP compared to 
9H.
RESULTS—Over a 20-year period, treatment of LTBI with 3HP rather than 9H resulted in 5.2 
fewer cases of TB and 25 fewer lost QALYs per 1000 individuals treated. From the health system 
Correspondence to: Dylan Shepardson, Department of Mathematics and Statistics, Mount Holyoke College, 50 College St, South 
Hadley, MA 01075, USA. Fax: (+1) 413 538 3035. dshepard@mtholyoke.edu. 
*Assumed duration of treatment for TB disease (see Model Inputs and Assumptions).
†Mean length of hospitalization for patients hospitalized for TB disease (see Model Inputs and Assumptions).
‡Calculated based on the number of expected future years of life for an individual aged 35 years and 1 lost QALY per year of lost life, 
based on the 2007 US Life Tables.
§Calculated based on the number of expected future years of life for an individual aged 35 years, based on the 2007 US Life Tables 
and the 0.05 lost QALYs per year for individuals with previous TB disease.
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and societal perspectives, 3HP would cost respectively US$21 525 and $4294 more per TB case 
prevented, and respectively $4565 and $911 more per QALY gained.
CONCLUSIONS—3HP may be a cost-effective alternative to 9H, particularly if the cost of 
rifapentine decreases, the effectiveness of 3HP can be maintained without DOT, and 3HP 
treatment is limited to those with a high risk of progression to TB disease.
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Approximately 300 000 patients are treated for latent tuberculous infection (LTBI) each year 
in the United States,1 with the majority of the costs of treatment borne by tuberculosis (TB) 
control programs in the public health sector. The American Thoracic Society, the Centers for 
Disease Control and Prevention (CDC) and the Infectious Diseases Society of America have 
endorsed the treatment of LTBI to prevent the development of TB disease as a central 
strategy for controlling and eliminating TB in the United States.2
A large randomized controlled trial recently showed that a 12-dose combination regimen of 
weekly rifapentine (RPT) plus isoniazid (INH; 900 mg each, 3HP) administered as directly 
observed treatment (DOT) by a health care worker can be an effective alternative to the 
standard 9-month regimen of daily isoniazid (300 mg) self-administered by the patient (9H) 
for the treatment of LTBI among persons at high risk of progression to TB disease.3 Based 
on the evidence of this and other clinical trials,4,5 the CDC issued guidelines in December 
2011 recommending 3HP given weekly with DOT from a health care worker as an 
equivalent treatment alternative to daily self-administered 9H (the longstanding standard of 
care) for otherwise healthy adults with LTBI who are at high risk for developing TB 
disease.6 The shorter treatment duration of the 12-dose regimen makes it an attractive 
alternative to 9H for TB control programs, as patients undergoing the 12-dose treatment are 
expected to have increased acceptance, better adherence and higher rates of treatment 
completion.3 On the other hand, at current prices the cost of medication is substantially 
higher for 12 doses of RPT than for 270 doses of INH, and the current recommendation that 
the 12-dose regimen be administered via DOT adds appreciably to the treatment cost of this 
regimen for TB control programs. We analyzed and report on the costs and health outcomes 
associated with each LTBI treatment regimen to inform clinicians, policy makers and public 
health programs about the relative cost-effectiveness of 9H and 3HP for the treatment of 
LTBI among individuals at high risk for progressing to TB in the United States.
METHODS
We compared the relative cost and effectiveness of the two LTBI treatment regimens, 9H and 
3HP, using an individual-based stochastic simulation model implemented using NetLogo 
(Center for Connected Learning and Computer-Based Modeling, Northwestern University, 
Evanston, IL, USA),7 a free, publicly available modeling platform. The model tracks the 
costs and health outcomes of two simulated populations of 100 000 individuals with LTBI, 
one population treated with 9H and the other with 3HP, over 20 years following the start of 
LTBI treatment. The primary health outcomes considered were the occurrence of TB disease 
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and the loss of quality-adjusted life years (QALYs) due to the burden of LTBI treatment, 
LTBI treatment-related toxicity, TB disease and death. Costs are reported from two 
perspectives: the health system perspective, which includes hospital and clinic personnel 
time, medication, supplies, and medical and diagnostic procedures; and the societal 
perspective, which consists of health system costs plus patient out-of-pocket expenses and 
the economic value of lost patient productivity. Costs are in 2010 US dollars, and all future 
costs and health outcomes have been discounted at an annual rate of 3%.
The model input parameters were derived from four sources: a clinical trial comparing 9H 
and 3HP among persons at high risk for TB disease,3 data from a TB control program in the 
Nashville Public Health Department (a recruitment site for the clinical trial), data provided 
by United States government agencies and published literature. The base case analysis used 
the input parameter values shown in Table 1 and yielded the primary results in Table 2. In 
sensitivity analysis, each input parameter was allowed to vary independently from its base 
case value over a specified range (Table 3) to explore the variability of model output in 
response to changing input values. We also conducted multivariate sensitivity analyses in 
which two or more input parameters were varied simultaneously. Confidence intervals (CIs) 
quantifying stochastic variability in the model output were obtained by bootstrap resampling 
of simulation data.
At the start of the simulation, each individual is treated with 9H or 3HP. The age of each 
individual is drawn from the distribution of ages of participants at the time of enrollment in 
the clinical trial, and the number of doses taken follows the distribution of doses completed 
by clinical trial participants. Individuals are each assumed to undergo an initial clinic visit, 
and thereafter one follow-up visit for each month on treatment, with 3HP patients incurring 
additional costs related to the administration of each dose by DOT from the health care 
personnel. Costs associated with LTBI treatment clinic visits are based on data from the 
Nashville Public Health Department (Figure 1). Medication costs for RPT and INH ($0.05 
per 9H dose, $12.31 per 3HP dose) are prices available to the US Department of Veterans 
Affairs through the Pharmaceutical Prime Vendor Program in 2010 (unpublished data, see 
Acknowledgements).
While undergoing treatment for LTBI, simulated individuals have a probability of drug 
toxicity or hospitalization based on the frequency of treatment-related adverse events and 
hospitalizations among clinical trial participants.3 As no treatment-related deaths were 
observed in the clinical trial, simulated individuals receiving LTBI treatment with either 9H 
or 3HP were assumed to experience a risk of death from drug toxicity equal to that 
previously observed in patients taking INH for up to 12 months (Table 1).12,13
During each year of simulation, individuals have a risk of progressing to TB disease that 
depends on the regimen and number of doses completed; for each infected individual, the 
risk of progression from LTBI to TB disease is assumed to be highest soon after infection 
and to decline over time.21 Individuals developing TB disease are assumed to receive 
treatment and incur costs based on this treatment, and to experience an elevated risk of death 
from TB disease. All individuals experience an age-specific annual risk of death from causes 
unrelated to TB.14 Each case of primary TB disease is assumed to give rise to additional 
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secondary cases due to transmission based on data from genotyping studies and contact 
investigations.17–20 For the societal perspective only, patient time spent in clinic visits, 
receiving DOT or being hospitalized due to severe LTBI drug toxicity or TB disease is 
valued based on economic productivity estimates for the US population (Table 1).15,16 
Individuals experiencing drug toxicity or TB disease are assumed to have additional costs 
and reduced quality of life. Quality of life estimates used are those published in a previous 
cost-effectiveness analysis of LTBI treatment regimens (Table 1).8
A detailed description of the model and its input parameters, as well as the model itself with 
modifiable parameters and the associated source code, are available in the Appendix to this 
report.*
As human subjects were not involved, ethics approval was not required for this study.
RESULTS
In the base case analysis, using the specified input parameter values (Table 1), treatment 
with 3HP prevents an average of 5.2 (95%CI 4.5–5.9) additional TB cases and 25 (95%CI 
21–29) lost QALYs per 1000 LTBI treatment starts when compared to 9H. From the health 
system perspective, 3HP costs more than 9H by $112 (95%CI 99–129) per person treated, 
while from the societal perspective 3HP is more costly by $23 (95%CI 7–41) per person 
treated (Table 2). The upfront cost of LTBI treatment is higher for 3HP than for 9H, with 
3HP recovering some of those costs over time by preventing more cases of active TB (Figure 
2).
From the health system perspective, the incremental cost per TB case prevented by 3HP vs. 
9H is $21 525 (95%CI 16 807–28 520), and the cost per QALY gained is $4565 (95%CI 
3584–5965). From the societal perspective, the incremental cost per TB case prevented by 
3HP vs. 9H is $4294 (95%CI 1156–8908), and the cost per QALY gained is $911 (95%CI 
268–1826; Table 2). Although there is no official threshold for determining the cost-
effectiveness of public health interventions in the United States, interventions costing less 
than $50 000/QALY gained have been deemed cost-effective by some health economists.22 
Until estimates of willingness to pay and opportunity costs of expenditures on LTBI 
treatment become available, our analysis suggests that 3HP might be a cost-effective and 
affordable alternative to 9H for the treatment of LTBI in individuals at high risk for 
developing TB in the United States.
In univariate sensitivity analyses, individual input parameters were independently varied 
while holding all other inputs at their base case values. The results of the univariate 
sensitivity analyses are shown in Table 3, with the shaded cells denoting scenarios where 
3HP is cost-saving compared to 9H. The incremental cost per TB case prevented by 3HP 
compared to 9H ranged widely, but the incremental cost per QALY gained was consistently 
below $20 000.
*The Appendix is available in the online version of this article at http://www.ingentaconnect.com/content/iuatld/ijtld/
2013/00000017/00000012/art00006
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The cost of RPT and the cost of providing DOT are both very influential in determining the 
cost-effectiveness of 3HP relative to 9H, as they are both upfront costs incurred with each 
dose taken and apply only to patients receiving 3HP. A decrease in the cost of RPT or the 
cost of DOT has the potential to improve the cost-effectiveness of 3HP considerably. An 
RPT cost of $10 per 900 mg dose is the value at which 3HP becomes cost-saving relative to 
9H from the societal perspective, and setting the DOT cost to $0 (as for self-administered 
treatment) renders 3HP cost-saving compared to 9H from both the health system and 
societal perspectives. On the other hand, the current average wholesale price of RPT is 
$24.89 per 900 mg dose,23 about double the cost used in the base case analysis based on 
prices available to the United States Department of Veterans Affairs. Similarly, 
approximately doubling the cost of DOT from $17.76 per dose to $35 per dose more than 
doubles the incremental costs of 3HP per TB case prevented and per QALY gained 
compared to 9H (Table 3).
The baseline risk of progression from LTBI to TB disease was varied from 50% to 200% of 
the base case value for all individuals, regardless of regimen, to explore the possible effects 
of treating individuals with lower or higher risk of progression from LTBI to TB disease 
than those studied in the clinical trial. When the risk of progression to TB disease is lower, 
the cost-effectiveness of 3HP decreases substantially. As the risk of progression to TB 
disease increases for all individuals, 3HP is found to be increasingly cost-effective relative to 
9H. Similarly, higher rates of secondary transmission and higher costs of treating TB disease 
lead to 3HP being more cost-effective relative to 9H (Table 3).
Decreasing levels of adherence to either 9H or 3HP while maintaining other model inputs at 
their base case values leads to more TB cases, but the increased cost due to TB disease is 
offset in part by lower LTBI treatment costs. However, as there are very few data on the TB 
risk of individuals completing a partial course of 3HP, it is difficult to predict the effect of 
decreased adherence, making sensitivity analyses around 3HP adherence particularly 
speculative.
In the referenced clinical trial, patients receiving 3HP developed TB at approximately half 
the rate of those receiving 9H, and our base case analysis is based on these data. The clinical 
trial investigators concluded that 3HP is at least as effective in preventing TB disease as 9H.3 
In sensitivity analysis, we tested the case that 3HP and 9H have equivalent effectiveness by 
setting the baseline risk of progression to TB disease for both regimens to the level observed 
among all individuals receiving 9H in the clinical trial. Under this scenario, as expected, 
there was on average an equal number of TB cases among individuals receiving 3HP as 9H, 
and the incremental cost per QALY gained increased while remaining below $20 000. 
Additional results and discussion of multivariate sensitivity analyses are provided in the 
Appendix.
DISCUSSION
The 3HP regimen is more costly than 9H due mainly to the higher cost of medication and 
the current recommendation that doses be administered by DOT from health care personnel. 
Over the long term, 3HP recovers some of these upfront costs by preventing more cases of 
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TB. When compared to 9H, 3HP reduces the number of clinic visits during LTBI treatment 
and the number of future cases of TB.
Over a wide range of sensitivity analyses, the incremental cost per QALY gained by 3HP 
compared to 9H was found to be less than $20 000. As 3HP, when compared to 9H for the 
treatment of LTBI, incurs incremental costs per QALY gained that are within the range of 
values for many commonly accepted public health interventions, 3HP could be judged to be 
a cost-effective alternative to 9H for the treatment of LTBI.22
Lowering the cost of RPT to public health programs has the potential to dramatically 
improve the cost-effectiveness of the 3HP regimen. Similarly, if it is possible to eliminate or 
relax the requirement for DOT while maintaining acceptable levels of adherence, 
effectiveness and safety, the cost-effectiveness of 3HP would improve substantially. For 
instance, in the base case the model assumes that each individual receives each dose by DOT 
from a health care worker who travels to the patient. If the patient is instead assumed to 
receive one 3HP dose by DOT during each scheduled clinic visit (so that a complete 12-dose 
course of 3HP involves 9 visits from a health care worker rather than 12), then 3HP becomes 
cost-saving relative to 9H from the societal perspective.
In populations where the risk of developing TB is lower than among the high-risk patients 
enrolled in the clinical trial,3 the cost-effectiveness of 3HP is projected to be less favorable 
because the number of cases of TB prevented by 3HP (relative to 9H) will be lower. 
Conversely, in populations with a higher risk of developing TB, the cost-effectiveness of 
3HP has the potential to be more favorable because the number of TB cases prevented by 
3HP (relative to 9H) will be higher. Care should be taken in extrapolating our findings to 
high-risk subpopulations (e.g., children and people infected with the human 
immunodeficiency virus), for whom a limited amount of data is available on the safety and 
effectiveness of 3HP. Our analysis projects that the costs related to LTBI drug toxicity are 
relatively minor for both regimens in comparison to the costs arising from LTBI treatment 
and future TB disease (Figure 2).
While 3HP appears to be an attractive alternative to standard LTBI treatment with 9H from 
the health system and societal perspectives, local and individual circumstances need to be 
considered when choosing a regimen. For example, drug costs, the cost of providing DOT, 
program feasibility, perceived risk of progression to TB disease and the length of the 
window of opportunity for intervention are important factors when making decisions 
regarding LTBI treatment. To further refine strategies and decisions regarding LTBI 
treatment by programs and clinicians, additional studies are needed to assess both the 
adherence to and the level of protection offered by a self-administered 3HP regimen, and the 
relative risk of progressing to TB disease among various groups of persons with LTBI.
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APPENDIX. MODEL INPUTS AND ASSUMPTIONS
Tuberculosis disease progression
Tuberculosis (TB) activation rates for the first 3 years after treatment initiation are taken to 
be the rates per 100 person-years observed in the clinical trial population1 based on the 
number of doses taken. The breakdown by doses completed was obtained from the TB Trials 
Consortium Data Coordinating Center and is presented in Table A.1. Activation risk is 
assumed to drop by 50% each year thereafter, to a minimum of 5% of the original (year 0) 
risk, based on the rate of decline in case rates among foreign-born persons after arrival in the 
United States, as presented in Figure A.1 from Cain et al.2 The assumption of an annual 
decrease of 50% and minimum TB rate of 5% of the original gives a steeper decline and 
lower floor than appears in Cain et al.,2 making it conservative with respect to the 3HP 
regimen (12-dose regimen of weekly rifapentine plus isoniazid), as a higher background TB 
activation rate improves the relative cost-effectiveness of 3HP in the base case analysis.
Individuals developing active TB were assumed to receive treatment, and costs were 
assessed accordingly (see below). Individuals developing active TB were assumed to have a 
one-time risk of death of 5.8% for a reason related to their TB disease in the same simulated 
year, the most up-to-date estimate for the US population based on unpublished surveillance 
data (personal communication, S Beavers, Surveillance, Epidemiology, and Outbreak 
Investigations Branch, Division of Tuberculosis Elimination, Centers for Disease Control 
and Prevention [CDC]) finding that 5.8% of US TB patients die of TB-related causes either 
before diagnosis or during anti-tuberculosis treatment. In sensitivity analysis, this risk of 
death varied between 2% and 15%, with relatively minor effects on the relative cost-
effectiveness of 3HP as compared to 9H (see Table A.10, and Table 3 in the main article).
Shepardson et al. Page 8
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2017 May 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lost productivity due to premature death from TB is not included in the model. These 
estimates are sometimes included in economic analyses conducted from the societal 
perspective, based on expected lifetime production of individuals who die prematurely, and 
can dramatically improve the apparent cost-effectiveness of health interventions. Grosse et 
al. estimate the present value of lifetime production for individuals in their early 40s at 
approximately 1 million 2007 US dollars, with a 3% annual discount rate.3 Estimates of 
future individual productivity, however, are somewhat speculative and do not include future 
societal costs that individuals dying prematurely would otherwise have incurred over a 
longer lifetime, and can therefore give an inflated estimate of the total societal cost of 
premature deaths. Inclusion of lost productivity due to premature TB-related death would 
tend to improve the cost-effectiveness of 3HP relative to 9H (9 months of daily, self-
administered isoniazid) under the base case assumption that 3HP prevents more future cases 
of active TB and deaths from TB disease.
Table A.1
Tuberculosis case rates and doses taken for patients participating in a clinical trial comparing 
3HP with 9H;1 the follow-up period was 33 months
Cases py follow-up Cases per 100 py follow-up
9H
 0–90 doses 5 1377 0.36
 91–240 doses 4 1413 0.28
 241+ doses 6 7134 0.08
3HP
 0–8 doses 2 1503 0.13
 9+ doses 5 9116 0.05
3HP = 12-dose regimen of weekly rifapentine plus isoniazid; 9H = 9 months of daily, self-administered isoniazid; py = 
person-years.
Figure A.1. 
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Distribution of ages of clinical trial participants at the time of enrollment in the clinical trial: 
mean: 36 years; median: 35 years; maximum: 103 years; minimum: 2 years. Data provided 
by the Tuberculosis Trials Consortium Data Coordinating Center.
Secondary cases due to transmission
The average number of secondary TB cases due to transmission from an individual with 
active TB, including secondary cases that develop soon after the transmission occurs and 
secondary cases that develop later due to latent tuberculous infection (LTBI) acquired 
directly from the primary source case, were estimated from the following sources.
1. Recent cross-sectional studies of TB genotyping data in the United States 
estimate that 23% of TB cases in the United States (13.2% in the US-born 
population and 9.8% in the foreign-born population) can be attributed to recent 
transmission (as opposed to reactivation of previously acquired LTBI).4,5 
Assuming that US TB incidence rates are nearly constant over the short term and 
that cases due to recent transmission were infected by previously documented 
US TB cases, each primary case must generate 0.23 secondary TB cases in the 
short term via recent transmission. Under the common assumption that an equal 
number of cases will arise due to later activation of LTBI acquired via 
transmission (see, for example, Dye6), each primary active TB case will 
eventually lead to 0.46 secondary TB cases.
2. A recent study in the Netherlands used genotyping data for 5185 pulmonary TB 
patients to determine that on average 0.24 secondary TB cases occur per primary 
case within 2 years of diagnosis of the primary case.7 Assuming, as above, that 
an equal number of secondary cases will arise due to later activation of 
transmitted LTBI, this suggests that each primary active TB case eventually leads 
to 0.48 secondary TB cases. Although TB incidence in the Netherlands is 7.3 per 
100 000 population, higher than the US rate of 4.1/100 000, the estimated 
fraction of cases due to recent transmission is very similar in the US 
population4,5 and the Dutch population.7
3. A 1999 genotyping study involving TB patients in San Francisco, CA, United 
States, found 183 secondary cases and 1059 primary cases, or 0.17 secondary 
cases per primary case over the period 1991–1996.8 Assuming that an equal 
number of cases will arise due to later activation of transmitted LTBI, we get 
0.34 secondary TB cases per primary case.
4. A 2002 study of contacts of 349 US patients with culture-positive pulmonary TB 
yielded 3824 contacts.9 Of these, 2095 were screened, with 24 found to have 
active TB and 655 found to have LTBI (initial tuberculin skin test [TST] positive 
or skin test converter). Extrapolating these results to those who were not 
screened, we would expect 44 TB cases and 1196 contacts with LTBI from the 
349 primary TB cases. Assuming that 10% of those with LTBI will eventually 
develop active TB, this gives 164 secondary TB cases from 349 primary cases, or 
0.47 secondary TB cases per primary case.
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5. In a 2000 study of close contacts of pulmonary smear-positive TB patients in the 
United States,10 the mean number of close contacts per patient was 6. Total TST 
positivity among contacts was 36%, and 2% had active TB. On this basis, and 
assuming, as is conventional,6 that 10% of those who are TST-positive will 
eventually develop active TB, the number of secondary TB cases per smear-
positive primary case is estimated to be (2%*6 + 36%*10%*6) = 0.34. A 1999 
study involving TB patients in San Francisco found that smear-negative primary 
TB cases were responsible for 17% of TB transmission,8 which suggests that the 
transmission rate for smear-negative individuals is 0.07. A 2004 study in Canada 
found 17–22%,11 while a 2008 study in the Netherlands found 13%.12 As 33% 
of US TB cases are thought to be smear-positive,13 the number of secondary 
cases per primary case is therefore estimated to be (0.33*0.34 + 0.67*0.07) = 
0.16. This study reported infection and disease status only for close contacts 
(45% of all contacts identified) of primary TB cases; unpublished data from the 
same study (personal communication, S Marks, Division of TB Elimination, 
CDC) shows that 21% of casual contacts were TST-positive and 0.24% had 
active TB. There were seven casual contacts per index case. Using the same 
calculations described above, we get an additional (0.24%*7 + 21%* 10%*7) = 
0.16 secondary TB cases per smear-positive primary case from smear-positive 
casual contacts, and (0.33* 0.16 + 0.67*0.03) = 0.07 secondary TB cases per 
primary case (any smear status) in casual contacts. Thus, when casual contacts 
are included, this gives 0.23 secondary TB cases per primary TB case among 
those identified as contacts. The estimates in both #4 and #5 are subject to the 
limitations that not all contacts with TB or LTBI will have acquired this via 
transmission from the index case, and the set of contacts investigated may not 
include every individual who will eventually develop TB due to transmission 
from an index case.
6. In a modeling paper from 1998,14 a differential equation model for TB in the US 
population was fitted to US TB surveillance data. The authors found that R = 
0.55 achieved a good fit for most of the previous century’s TB incidence data, 
where R represents the number of secondary TB cases per primary TB case. 
They used R = 0.55 to project 1.2 additional TB cases per primary TB case, 
assuming an infinite transmission chain, whereas we consider only secondary TB 
cases from transmission in the present analysis.
The base case value used in the model was 0.46 secondary TB cases due to transmission per 
primary case based on the estimate using genotyping data for the US population (#1), which 
is consistent with estimates based on genotyping in the Netherlands (#2) and one study of 
contacts to individuals with TB in the United States (#4). In consideration of the alternative 
estimates and sources above, the parameter was varied over the range 0.0–0.6 in sensitivity 
analysis. For the purpose of discounting, one third of secondary TB cases due to 
transmission are assumed to occur immediately following exposure to the infected primary 
case, with an additional third after 5 years, and the remaining third after 25 years. The model 
does not consider transmission beyond a secondary case. Inclusion of additional links in the 
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transmission chain would favor the regimen that prevents more primary cases of TB in the 
cost-effectiveness analysis.
Patients’ indirect costs
Hourly indirect costs for LTBI patients due to lost productivity during LTBI treatment are 
estimated based on average per capita income for the United States,15 based on dividing 
2010 annual per capita income ($26 487) by 2080* annual working hours to get $12.73 per 
hour. Lost patient productivity due to overnight or multiple-day hospitalization is valued at 
$139 per day hospitalized based on economic productivity estimates for the US population 
in 2007,3 with values adjusted for inflation to 2010 US dollars based on average weekly 
earnings from the Current Population Survey.16
LTBI treatment
LTBI treatment costs
LTBI treatment costs for 3HP and 9H were calculated based on detailed personnel time and 
supply cost data collected from the Nashville Public Health Department. Fixed overhead 
costs were not included in the analysis. Simulated patients in the model underwent an initial 
clinic visit and one monthly follow-up clinic visit for each month of treatment for LTBI with 
either 9H or 3HP. The initial clinic visit included chest X-ray, liver function test (LFT), 
complete blood count (CBC), human immunodeficiency virus (HIV) testing, and 
examination by a provider. Follow-up clinic visits included examination by a clinic nurse, 
and for 5% of follow-up clinic visits additional laboratory work and examination by a 
provider was also required. Laboratory and supply costs for initial and monthly follow-up 
clinic visits are tabulated in Table A.2. Personnel and patient time for initial and follow-up 
clinic visits are given in Table A.3 and Table A.4, respectively.
Salaries for clinic personnel were estimated based on the Occupational Employment 
Statistics data reported by the Bureau of Labor Statistics,18 and are given in Table A.5. 
Personnel costs were calculated including wages plus estimated fringe benefits, as 
recommended in Haddix et al.19
Personnel costs for initial and follow-up clinic visits were calculated by multiplying 
personnel hours per visit (Table A.3 and A.4) by the hourly personnel cost (Table A.5). Total 
patient and personnel costs for initial and follow-up visits were calculated by multiplying 
personnel hours by hourly wage are given in Table A.6.
*The Bureau of Labor Statistics calculates annual wages by multiplying the hourly mean wage by 2080 hours; we have used the same 
estimate of 2080 annual employment hours.
Shepardson et al. Page 12
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2017 May 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Table A.2
Laboratory and supply costs (excluding medication) for initial and monthly scheduled 
follow-up clinic visits for LTBI treatment by either 9H or 3HP*
Initial visit US$ Follow-up visit US$
Reception
 Paper 0.02 0.01
 Chart × 1 0.16
 Filing stickers 0.18
Nurse’s office
 Paper forms 0.06 0.01
 Temperature probe covers × 1 0.03 0.03
 Language LINE interpreter services 5.59† 2.95‡
 Appointment cards 0.03 0.03
Diagnostic/screening tests
 Gloves × 2 pairs 0.18
 Urine container × 1 0.17 0.01
 Pregnancy test kit × 1 2.50
 Vacutainers × 1 0.15 0.01
 Needle vacutainers × 1 0.15 0.01
 Biohazard bags for transporting blood samples 0.04 0.00
 Chest X-ray × 1 12.00§
 Paper gowns × 1 0.32
 LFT laboratory cost 5.40 0.27
 HIV laboratory cost 19.65¶
 Laboratory cost of complete blood count 5.40
Provider’s office
 Language line interpreter services 4.05† 0.16‡
 Exam table paper 0.03 0.03
 Otoscope covers 0.04 0.04
 Total (female) 56.15 3.56
 Total (male) 53.65 3.56
 Total (average) 54.90 3.56
*
Except for HIV laboratory cost,17 data were collected from the Nashville Public Health Department; costs for follow-up 
visits are based on patients seeing a provider or requiring more extensive workup during 5% of follow-up visits.
†Average Language Line Services cost per month for all new treatment starts is $578.40. The clinic averages 60 new LTBI 
treatment starts per month, which amounts to $9.64 per patient. Patients average 58% of visit time with clinic nurses and 
42% with providers during the initial clinic visit.
‡Average Language Line Services cost per month for all follow-up visits is $746.60. The clinic averages 240 LTBI follow-
up visits per month, which amounts to $3.11 per patient.
§Cost is for acquisition of X-ray only; personnel cost of reading the X-ray is included under physician time in Table A.3.
¶Center for Medicare and Medicaid Services 2010 Clinical Laboratory Fee Schedule, http://www.cms.gov.17
LTBI = latent tuberculous infection; 9H = 9 months of daily, self-administered isoniazid; 3HP = 12-dose regimen of weekly 
rifapentine plus isoniazid; LFT = lung function test; HIV = human immunodeficiency virus.
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The cost of administering medication via directly observed therapy (DOT) was gathered 
from the Nashville Public Health Department based on the value of staff time and 
transportation (Table A.7). DOT doses were administered by outreach workers who traveled 
to the patients. Outreach worker time per dose administered was calculated by dividing the 
number of weekly outreach worker hours (160 total weekly hours for four full-time outreach 
workers) by the average number of weekly DOT doses administered in the field by the 
program (286 doses) to get a mean of 34 min per DOT dose administered. Outreach workers 
traveled an average of 4 miles per dose administered, and were reimbursed at a rate of $0.51 
per mile. Patient time was 8.5 min per DOT dose received. Outreach worker average travel 
time per DOT dose was significantly less than patient travel time to the clinic due to 1) more 
than one DOT dose being administered (to more than one patient) during some DOT visits 
and 2) outreach workers traveled by car, while many patients traveled by public 
transportation. DOT costs are presented in Table A.7. Simulated patients receiving the 3HP 
regimen were assumed to have one clinic visit and four weekly DOT visits for each month 
on treatment (three clinic visits and 12 DOT visits for those who complete all 12 doses). 
Simulated patients receiving the 9H regimen, which is self-administered by the patient, did 
not require DOT and were assumed to have one monthly clinic visit for each month on 
treatment (nine clinic visits for those completing all 270 doses); 8.5 min of patient time was 
included for each dose taken by DOT based on data reported by the Nashville Department of 
Public Health for the societal perspective analysis. No additional per-dose patient time was 
added for patients taking 9H (although for 270 doses a small amount of patient time per dose 
does add up: 30 s per dose would add more than 2 h of patient time and $29 in patient costs 
to the societal perspective analysis for complete 270-dose treatment). Inclusion of this 
additional patient time would make 3HP more cost-effective than 9H from the societal 
perspective.
Table A.3
Patient and personnel time for initial LTBI treatment clinic visits; data were collected from 
the Nashville Public Health Department
Patient Receptionist Clinic nurse CXR technician Provider Interpreter (if needed)*
Travel time
 From home/work to clinic 27.5
 From clinic to home/work 27.5
 Reception
 Sign-in 2.5 2.5
 Reception processing 8.0
Patient wait time to see nurse 12.0
 Nurse’s office before patient 
sees provider
 Moving to nurse’s office 1.0 1.0 1.0
 Urine collection (pregnancy 
test)
4.0 4.0
 LTBI education with nurse 10.0 10.0 10.0
 LTBI education without nurse 10.5 10.5
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Patient Receptionist Clinic nurse CXR technician Provider Interpreter (if needed)*
 Initial workup (sputum smear, 
medical history, vital signs)
13.5 13.5 13.5
Blood collection 6.0 6.0 6.0
 Diagnostic/screening tests
 CXR 12.0 12.0 12.0
 LFT paperwork/processing 2.0
 CBC paperwork/processing 2.0
 HIV paperwork/processing 2.0
Pregnancy paperwork/processing 2.0
 Provider’s office
 Escort to provider’s office 1.5 1.5 1.5
 Patient’s wait time for 
provider
8.0 8.0
 Review CXR results 2.0 2.0 2.0
 History taken 12.5 12.5 12.5
 Physical examination 4.5 4.5 4.5
Documentation 5.0
 Nurse’s office after patient 
sees provider
 Medication prepared 2.0
 Medication dispensed 3.0 3.0 3.0
 Appointment scheduling 3.5 3.5 5.0
 Documentation 4.5
 Return chart to reception 1.0 1.0
Total (female) 164.5 11.5 54.0 12.0 24.0 93.5
Total (male) 160.5 11.5 52.0 12.0 24.0 89.5
Total (average) 162.5 11.5 53.0 12.0 24.0 24.76
*54% of LTBI patients (new and follow-up) were non-English speaking and needed an interpreter. Of those, half spoke 
languages for which there were on-site interpreters (Spanish/Arabic/Somali/Amharic); Language Line services were 
therefore not needed. The average interpreter time per patient is therefore 27% of the interpreter time for each individual 
who required an interpreter.
LTBI = latent tuberculous infection; CXR = chest X-ray; LFT = liver function test; HIV = human immunodeficiency virus.
Medication costs are estimated based on those paid by the Department of Veterans Affairs in 
2010 under the Pharmaceutical Prime Vendor program (32 × 150 mg rifapentine [RPT] 
tablets cost $64.82, 100 × 300 mg isoniazid [INH] tablets cost $5.28). The cost per 300 mg 
dose of INH for the 9H regimen is $0.053. For the 3HP regimen, the cost per (900 mg RPT 
+ 900 mg INH) dose is $12.31.
The total cost of treatment by 9H or 3HP is presented in Table A.8, including supply and 
personnel costs of clinic visits, medication costs, DOT cost, and (for the societal perspective 
only) patient direct and indirect costs.
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Distribution of doses taken
Patient costs were computed in the model based on the number of doses taken by each 
simulated patient (e.g., patients who completed only 5 doses of the 3HP regimen would 
incur costs for the initial clinic visit, one monthly follow-up visit, 5 doses of medication, and 
5 DOT visits). The distribution of doses taken by patients in the simulation was the 
distribution of doses completed by participants in the clinical trial.1 This distribution was not 
published, but was obtained from the Tuberculosis Trials Consortium Data Coordinating 
Center and is reproduced in Table A.9.
Table A.4
Patient and personnel time for monthly follow-up LTBI treatment clinic visits*
Patient Receptionist Clinic nurse Provider Interpreter (if needed)†
Travel time
 From home/work to clinic 27.5
 From clinic to home/work 27.5
Reception
 Sign-in 2.0 2.0
 Reception processing 8.0
 Patient wait time to see nurse 12.0
Nurse
 Moving to nurse’s office 1.0 1.0 1.0
 History/vital signs/symptoms 9.0 9.0 9.0
 Dispensing meds 5.0 5.0 5.0
 Documentation 4.5
 Return chart to reception 1.0
 Appointment scheduling 2.0 2.0
 Urine collection, if needed‡ 4.0 4.0
 Blood collection, if needed‡ 6.0 6.0 6.0
Provider if needed (5% of patients)
 Escort to provider’s office 1.0 1.0 1.0
 Patient’s wait time for provider 7.5 7.5
 Assessing issue 7.5 7.5 7.5
 Documentation 2.5
Contact patient for missed visit (25% of patients)
 Attempt 1 7.5
 Attempt 2 3.5
 Attempt 3 3.5
  Total 87.3 13.6 22.9 0.5 4.47
*
Data were collected from the Nashville Public Health Department: all times are reported in minutes and have been 
rounded to the nearest minute.
†54% of LTBI patients (new and follow-up) were non-English speaking and needed an interpreter. Of these, half spoke 
languages for which there were on-site interpreters (Spanish/Arabic/Somali/Amharic); Language Line services were 
therefore not needed. The average interpreter time per patient is therefore 27% of the interpreter time for each individual 
who required an interpreter.
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‡Applies to 5% of patients.
LTBI = latent tuberculous infection.
Table A.5
Clinic personnel wages for LTBI treatment clinic visits*
Position BLS occupation title BLS code
Mean 
hourly 
wage US
$
Hourly 
wage + 
benefits† 
US$
Mean 
annual 
wage US
$
Annual 
wage + 
benefits† 
US$
Receptionist Medical records and health 
information technicians
292017 15.12 20.83 31 440 43 306
Clinic nurse Registered nurses 291111 32.47 44.72 67 550 93 044
X-ray technician Radiologic technologists 
and technicians
292037 25.76 35.48 53 590 73 815
Provider Internists, general 291063 93.96 129.42 195440 269201
Interpreter‡ Medical records and health 
information technicians
292017 15.12 20.83 31 440 43 306
Outreach worker Licensed practical and 
licensed vocational nurses
292061 20.14 27.74 41 890 57 699.72
*
From the May 2010 Occupational Employment Statistics Survey by the Bureau of Labor Statistics (Industry: Outpatient 
Care Centers, North American Industry Classification System code 621400).18
†
Fringe benefits calculated based on assumption that wages account for 72.6% of employee compensation (Haddix et al., 
Appendix I).19
‡
For the purpose of calculating cost, interpreter duties are assumed to be performed by personnel with the hourly wage rate 
of a clinic receptionist.
LTBI = latent tuberculous infection; BLS = Bureau of Labor Statistics.
Table A.6
Patient and clinic personnel costs for initial clinic visit and monthly follow-up visit for LTBI 
treatment; medication and supply costs not included in totals
Hourly compensation US$
Initial visit Follow-up visit
Time min Cost US$ Time min Cost US$
Receptionist 20.83 11.5 3.99 13.625 4.73
Clinic nurse 44.72 53 39.51 22.85 17.03
CXR technician 35.48 12 7.10 0 0.00
Provider 129.42 24 51.77 0.5 1.08
Interpreter* 20.83 24.705 8.58 4.401 1.53
Patient 12.73 159.5 33.85 87.3 18.53
Clinic personnel total 110.94 24.37
Patient round trip bus fare 3.20 3.20
Patient total 37.05 21.73
*
The average interpreter time is 27% of the interpreter time for each individual who required an interpreter (see note to 
Tables A.3 and A.4).
LTBI = latent tuberculous infection; CXR = chest X-ray.
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Table A.7
DOT costs per dose administered*
Cost
DOT component US$
Patient time per dose, min 8.5
DOT worker time per dose, min 34
DOT worker cost per dose 15.72
Driving cost per dose (6.44 km @ $0.82/km, from Nashville site) 2.04
Patient cost per dose 1.80
Total (health system) 17.76
Total (societal) 19.56
*
Patient and outreach worker time per dose and driving cost per dose are from the Nashville Public Health Department. 
Patient time is valued at $12.73 per hour here and elsewhere based on 2010 US per capita income; outreach worker time is 
valued at $27.74 per hour (see Table A.5). Health system costs do not include costs to the patient; societal costs include all 
health system costs plus patient costs.
DOT = directly observed therapy.
Table A.8
Cost of LTBI treatment by 9H or 3HP*
Category Cost US$ Source
Initial clinic visit
 Personnel cost 110.94 Table A.2
 Patient cost 37.05
 Supply cost 54.90 Table A.2
 Total health system 165.84 Supply cost + personnel cost
 Total societal 202.89 Supply cost + personnel cost + patient cost
Follow-up clinic visit
 Personnel cost 24.37 Table A.6
 Patient cost 21.73
 Supply cost 3.56 Table A.2
 Total health system 27.92 Supply cost + personnel cost
 Total societal 49.65 Supply cost + personnel cost + patient cost
DOT, per dose Table A.7
 Health system 17.76
 Societal 19.56
Medication cost, per month on treatment† Department of Veterans Affairs Pharmaceutical 
Prime Vendor Program
 9H (30 × 300 mg INH) 1.58
 3HP (4 × 900 mg INH + 4 × 900 mg RPT) 49.25
9H total treatment cost, per patient completing 270 
doses‡
Based on 1 initial clinic visit, 8 monthly follow-up 
clinic visits, and 9 months of medication
 Health system 403.45
 Societal 614.32
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Category Cost US$ Source
3HP total treatment cost, per patient completing 12 
doses‡
Based on 1 initial clinic visit, 2 monthly follow-up 
clinic visits, 3 months of medication, and 12 DOT 
visits
 Health system 582.55
 Societal 684.71
*
Health system costs do not include costs to the patient; societal costs include all health system costs plus patient costs. 
Clinic visit costs include supplies, clinic personnel time, and (for the societal perspective only) patient time and bus fare. 
Medication costs are not included in clinic visit costs.
†
Medication costs are borne by the health system.
‡
LTBI treatment costs for simulated patients depend on the number of doses taken; on average they are less than the cost of 
completed treatment because of the possibility of non-adherence.
LTBI = latent tuberculous infection; 9H = 9 months of daily, self-administered INH; 3HP = 12-dose regimen of weekly 
RPT plus INH; INH = isoniazid; RPT = rifapentine.
Table A.9
Distributions of doses taken by clinical trial participants1 for each regimen (9H and 3HP)*
3HP 9H
Doses taken Patients % Cumulative % Months on treatment Patients % Cumulative %
0 2.53 2.53 1 9.42 9.42
1 2.39 4.92 2 3.76 13.18
2 1.83 6.76 3 3.66 16.84
3 2.39 9.14 4 2.69 19.52
4 2.29 11.44 5 2.53 22.06
5 1.47 12.91 6 2.20 24.26
6 1.13 14.04 7 1.87 26.13
7 1.09 15.13 8 5.42 31.55
8 1.18 16.31 9 66.89 98.44
9 0.63 16.94 10 1.56 100.00
10 0.29 17.23
11 1.91 19.13
12 80.63 99.76
13 0.22 99.98
14 0.00 99.98
15 0.00 99.98
16 0.00 99.98
17 0.02 100.00
*
Data from the Tuberculosis Trials Consortium Data Coordinating Center.
9H = 9 months of daily, self-administered isoniazid; 3HP = 12-dose regimen of weekly rifapentine plus isoniazid.
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Tuberculosis disease costs
Tuberculosis disease diagnostic costs (incurred by all patients in the model who develop 
active tuberculosis)
Burman et al. reported $354 for diagnosis costs in 1994 dollars based on the cost of three 
mycobacterial cultures, chest X-ray, CBC count, serum chemistry panel, 1 h of physician 
time and 2 h of nurse time.20 Our estimate includes three smears* (3 × $7.70), 3 cultures† (3 
× $15.48), and chest X-ray‡ ($30.97).19 As in Burman et al.,20 we add 1 h of physician time 
at $93.96/h and 2 h of nurse time at $32.47/h (using hourly wage estimates from the Bureau 
of Labor Statistics,17 as described above in the section on LTBI Treatment Costs), to obtain 
($100.51 + $93.96 + $64.94) = $259 diagnosis cost to the health system. For societal cost, 
we include 3 h patient lost productivity for a total of $298, where patient time is valued at an 
hourly rate of $12.73 based on US Census Bureau data,15 as described in the section on 
Patient Time Valuation above.
TB disease out-patient costs (incurred by all patients in the model who develop TB 
disease)
Simulated individuals developing active TB were assumed to receive treatment with a 
standard regimen of 8 weeks of INH, rifampin (RMP), pyrazinamide and ethambutol (5 days 
per week, 40 doses), followed by 18 weeks of INH and RMP (5 days/week, 90 doses),21 
with all doses given by DOT. Health system costs are those incurred by TB programs for 
medications and personnel to conduct DOT. Societal costs include health system costs as 
well as patient productivity losses. The cost of DOT was gathered from the Nashville Public 
Health Department ($17.76 health system or $19.56 societal cost per dose. The societal cost 
includes patient time of 8.5 min per dose; see Table A.7). This DOT cost may be an 
underestimate for patients with TB disease, as it was gathered for LTBI patients, many of 
whom receive DOT in congregate settings; patients with TB disease are much less likely to 
receive DOT in congregate settings. Underestimating the cost of out-patient treatment will 
tend to favor the cost-effectiveness of the regimen that prevents fewer cases of TB disease 
(9H, in the base case analysis) and is conservative with respect to the cost-effectiveness of 
the 3HP regimen.
As most TB programs purchase their medications through the Public Health Service (PHS), 
estimates of PHS drug prices are used. The estimated PHS cost of medication for the 130 
dose regimen is $390 in 2008 dollars or $416 in 2010 dollars (updated using the medical 
care index of the Consumer Price Index [CPI]22).
Patients being treated for TB disease are assumed to undergo six monthly clinic visits while 
receiving anti-tuberculosis treatment. The health system and societal costs of these visits are 
assumed to be the same as those for follow-up visits during LTBI treatment ($27.92 health 
system, $49.65 societal; see Table A.8). In addition, patients being treated for TB disease are 
*CPT Code 87206.†CPT Code 87116.‡CPT Code 71015.
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assumed to incur additional costs for two chest X-rays (2*$30.97) and two sputum cultures 
(2*$15.48).19 The health system cost of TB treatment is:
The societal cost of TB treatment is:
Table A.10
Results of univariate sensitivity analysis: cost per TB case prevented and cost per QALY 
gained by 3HP (compared to 9H) when varying one parameter value at a time*
Parameter
Health system perspective Societal perspective
Incremental cost per 
TB case prevented 
US$
Incremental cost per 
QALY gained US$
Incremental cost per 
TB case prevented 
US$
Incremental cost per 
QALY gained US$
Base case scenario 21525 4565 4294 911
Directly observed therapy cost/dose ($17.76)
 $0 <0 <0 <0 <0
 $35 56124 11902 38893 8248
3HP medication cost per dose ($12.31)
 $5 6 854 1 454 <0 <0
 $25 46992 9965 29762 6311
 $35 67061 14221 39796 8439
TB hospitalization probability (49%)
 0% 32855 6983 17188 3653
 75% 15140 3207 <0 <0
Proportional change in risk of progression to TB disease (100%)
 50% 47861 7163 19007 2845
 150% 8 002 2 001 <0 <0
 200% 1 941 594 <0 <0
Patient hourly time value ($12.73)
 $0 21525 4565 18669 3959
 $7.50 21525 4565 10200 2163
 $17.00 21525 4565 <0 <0
Secondary TB cases per primary case (0.46)
 0 34895 6436 12153 2242
 0.6 18753 4104 2665 583
9H completion proportion (68%)
 63% 14906 3248 1145 250
 57% 15170 3464 2648 605
 51% 11378 3183 1043 292
3HP completion proportion (83%)
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Parameter
Health system perspective Societal perspective
Incremental cost per 
TB case prevented 
US$
Incremental cost per 
QALY gained US$
Incremental cost per 
TB case prevented 
US$
Incremental cost per 
QALY gained US$
 76% 16969 3209 <0 <0
 69% 19259 3922 <0 <0
 62% 15220 2518 <0 <0
3HP toxicity probability (8.2%)
 3% 16629 3749 <0 <0
 13% 25458 5158 7686 1557
Probability of death from TB disease (5.8%)
 2% 21332 5655 3828 1015
 15% 21424 3856 3862 695
Cost of hospitalization for TB ($25 495)
 $10000 28411 6025 11181 2371
 $40000 15078 3197 <0 <0
Annual QALY loss from LTBI treatment (0.03)
 0 21525 9132 4294 1822
 0.06 21525 3043 4294 607
Annual QALY loss from previous TB (0.05)
 0 21525 5961 4294 1189
 0.10 21525 3698 4294 738
Annual QALY loss from drug toxicity (0.25)
 0 21525 4520 4294 902
 0.50 21525 4610 4294 920
Annual QALY loss from hospitalization (0.50)
 0 21525 4571 4294 912
 1.00 21525 4558 4294 909
Annual QALY loss from anti-tuberculosis treatment (0.10)
 0 21525 4613 4294 920
 0.20 21525 4517 4294 901
Discount rate (3%)
 0% 15 825 2 573 959 156
 5% 24766 5732 6184 1431
Simulation duration (20 years)
 5 years 29468 5717 8914 1729
 10 years 25052 5078 6342 1286
 50 years 17321 3931 1633 371
Cost of initial clinic visit ($166)†
 $125 21525 4565 4294 911
 $205 21525 4565 4294 911
Cost of follow-up clinic visit ($28)
 $20 28559 6056 11328 2402
 $35 15237 3231 <0 <0
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*
Base case values are reported in parentheses. Shaded entries (where the incremental cost-effectiveness ratios are negative) 
represent scenarios where 3HP is cost-saving compared to 9H. Simulation run for each set of parameter values with 100 
000 simulated individuals for each regimen. Costs are in 2010 US dollars.
†As the same cost of the initial clinic visit is incurred for all individuals regardless of regimen, it has no bearing on the 
relative cost-effectiveness of the two regimens.
TB = tuberculosis; QALY = quality-adjusted life years; 3HP = 12-dose regimen of weekly rifapentine plus isoniazid; 9H = 
9 months of daily, self-administered isoniazid; LTBI = latent tuberculous infection.
Tuberculosis disease hospitalization costs (incurred by those patients in the model who 
are hospitalized for tuberculosis disease)
Of patients who develop TB disease, 49% are assumed to be hospitalized due to TB 
disease.23 As per Taylor et al.,23 the average hospitalization cost per study participant 
excluding physician fees is $10 881 799/733 = $14 846 (1998 dollars) or $23 820 (2010 
dollars, updated using the CPI Medical Care Index). As this amount does not include 
physician fees, these were added separately. The mean length of hospitalization per patient 
was 24 days (S Marks, personal communication of unpublished data from Taylor et al.23). 
Brown et al. found that ‘the mean length of stay for patients with TB was 19.9 days’.24 
Physician fees per day for ‘Level 2’ hospitalization are $69.78*.19 The total mean health 
system cost of hospitalization for TB disease, then, is estimated to be ($23 820 + 24*$69.78) 
= $25 495. Using $139 as the indirect cost to the patient of one day of hospitalization,3 the 
indirect patient cost due to hospitalization is (24* $139) = $3336 per patient hospitalized for 
active TB, and the total mean societal cost of hospitalization for active TB is estimated to be 
($25 495 + $3336) = $28 831. In recognition of the fact that the data for the cost of 
hospitalization for TB are more than 10 years old and these costs could be high, we 
considered in sensitivity analysis the extreme case that all individuals with TB disease are 
treated as out-patients by setting the model parameter governing the probability of 
hospitalization for TB disease to zero. See Table A.10 for the result of this and other 
sensitivity analyses.
The costs of patients diagnosed in hospital are not subtracted from the total hospitalization 
costs calculated, as detailed above (i.e., the 49% of TB patients who are hospitalized incur 
the $259 associated with diagnostic procedures in addition to the $25 495 associated with 
hospitalization). The costs associated with diagnostic procedures are computed using costs 
from the Center for Medicare and Medicaid Services 2010 Clinical Laboratory Fee 
Schedule, and are therefore reported in 2010 dollars.19 (The 1994 costs computed by 
Burman et al.20 are provided above for the sake of comparison only.)
Quality of life adjustments
Quality of life adjustments (also known as ‘health state utilities’ to health economists) for 
patient health states (LTBI treatment, LTBI drug toxicity, hospitalization, TB disease and 
previous TB disease) are those reported in Holland et al.25 These quality of life adjustments 
are applied over the duration of LTBI treatment, 2 weeks (drug toxicity), 6 months (active 
TB), the duration of hospitalization (7 days for severe toxicity, 24 days for TB) or the 
duration of life following TB activation, respectively. Simulated individuals are assumed not 
*CPT Code 99232.
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to incur reduced quality of life following LTBI treatment as long as they do not develop 
active TB, reflecting the fact that there is no evidence that individuals with LTBI who do not 
develop TB suffer any adverse health effects. Simulated individuals accrue no additional 
quality adjusted life years after death.
A number of studies have attempted to quantify the quality of life associated with TB-related 
health states.26–32 This is necessarily a subjective process, and there is no consensus on how 
best to measure quality of life. We allow quality-adjusted life year (QALY) values to vary 
widely in sensitivity analysis in recognition of the uncertainty associated with these 
parameters. In particular, the extent to which LTBI treatment and previous active TB disease 
have an impact on quality of life is unclear (a recent cost-effectiveness analysis of screening 
strategies for LTBI applied quality of life adjustments of 1 for time on LTBI treatment by 
INH and time with previous TB disease33). To explore this scenario, we performed a 
multivariate sensitivity analysis in which the quality of life adjustment for time on LTBI 
treatment and time with previous TB disease were simultaneously set to 1 to test these 
assumptions from Linas et al.,33 while holding other input parameters at their base case 
values.
Latent tuberculosis infection drug toxicity
LTBI drug toxicity rates for the 9H and 3HP regimens are estimated based on the rates of 
treatment-related adverse events and hospitalizations observed in the clinical trial,1 which 
found 332 treatment-related adverse events and 12 treatment-related hospitalizations in 4040 
treatment starts in the 3HP arm (8.2% and 0.3% of treatment starts, respectively) and 206 
treatment-related adverse events and 4 treatment-related hospitalizations in 3759 treatment 
starts in the 9H arm (5.5% and 0.1% of treatment starts, respectively).* As there were no 
drug toxicity-related deaths in the clinical trial, we assume the death rate due to drug toxicity 
to be 0.014% per treatment start for both 9H and 3HP, based on Saukkonen et al.34 and the 
International Union Against Tuberculosis’ follow-up of INH preventive therapy.35
The cost of LTBI drug toxicity is estimated as in a previous cost-effectiveness analysis 
comparing alternative treatment regimens for LTBI,25 with the costs updated to 2010 US 
dollars and an assumed 1 week of patient hospitalization time added (with patient time 
valued at $139 per day, as above) in the case of toxicity-related hospitalization for the 
societal perspective analysis. From Holland et al.,25 which relies on cost data from Taylor et 
al.,23 the health system cost for drug toxicity without hospitalization is taken to be $158 
(2008 dollars), or $169 in 2010 US dollars; the societal cost is assumed to be the same as the 
health system cost for toxicity without hospitalization. The health system cost for toxicity 
with 7 days of hospitalization is $5321 in 2008 dollars, or $5677 in 2010 US dollars; the 
societal cost for toxicity with 7 days of hospitalization is $5677 + 7*$139 = $6650 in 2010 
US dollars.
*Data on hospitalization for treatment-related adverse events has not previously been published and was provided by the Tuberculosis 
Trials Consortium Data Management Center.
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Background mortality and age distribution
In the base case analysis, patients were simulated for 20 years after starting treatment with 
either 9H or 3HP and experienced an annual risk of death unrelated to TB or LTBI treatment 
depending on their age (other simulation durations were explored in sensitivity analysis, see 
Table A.10). The age-specific risk of death due to events unrelated to TB or LTBI treatment 
was calculated using the 2007 US Life Tables.36 The distribution of ages of simulated 
patients at treatment start had a mean of 36 years and was the distribution of ages at 
enrollment in the clinical trial comparing 3HP and 9H1 (the age distribution of participants 
was not published, but was obtained from the authors).
Model description
The model is an individual-based (also known as ‘agent-based’) stochastic simulation 
developed using NetLogo 5.0 software (NorthWestern University, Evanston, IL, USA), 
which is freely available online.37 The model simulates two populations of individuals with 
LTBI. One simulated population is treated with 3HP, and the other is treated with 9H. 
Simulated individuals are followed for 20 simulated years after LTBI treatment, and costs 
and health outcomes related to LTBI treatment and TB disease are tracked during this time.
Initialization
During model initialization, two populations of individuals with LTBI are created, one 
receiving 3HP and one receiving 9H. Each simulated individual has an assigned set of 
attributes that are tracked over the course of the simulation. These include the individual’s 
age, LTBI regimen taken, number of doses completed, current risk of TB, and current state 
of health (on LTBI treatment, healthy post-LTBI treatment, TB disease, post-TB disease and 
dead). Time spent, cost and QALYs lost receiving treatment for LTBI, LTBI drug toxicity or 
TB disease are also tracked for each individual.
During the initialization phase, the random number generator for the stochastic simulation is 
first initialized with the seed 73939133. Each individual’s age is assigned by drawing from 
the distribution of ages of clinical trial participants at the time of enrollment (Figure A.1). 
Each individual is also assigned to complete an amount of treatment that is drawn from the 
distribution of the number of doses taken by participants in the referenced clinical trial for 
the appropriate regimen (Table A.9). For both regimens, individuals are assumed to have one 
initial clinic visit, followed by one follow-up clinic visit for each month on treatment starting 
with the second (a full 12-week course of 3HP therefore entails 1 initial clinic visit and 2 
follow-up visits; a full 9-month course of 9H entails 1 initial clinic visit and 8 follow-up 
visits). Each individual’s LTBI treatment costs are calculated based on the regimen and 
number of doses taken as follows:
1. For 3HP, the individual’s treatment cost is: (cost of initial clinic visit) + (cost of 
follow-up clinic visit)* (number of follow-up clinic visits) + (medication cost per 
dose + DOT cost per dose)*(number of doses taken).
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2. For 9H the individual’s treatment cost is: (cost of initial clinic visit) + (cost of 
follow-up clinic visit)* (number of follow-up clinic visits) + (medication cost per 
month)*(number of months on treatment).
For the societal perspective only, patient costs are added based on the number of minutes 
spent receiving treatment. For both regimens, individuals are assumed to spend (including 
travel time) 159.5 min at the initial clinic visit, and 87.3 min at each follow-up clinic visit 
(Tables A.4, A.5). For 3HP, individuals spend an additional 8.5 min for each dose taken 
receiving DOT from a health care worker (Table A.7). Patient time is valued at an hourly 
rate of $12.73, as described above. Individual patients are assumed to incur out-of-pocket 
costs of $3.20 for each clinic visit for a round trip bus fare.
Individuals experience lost QALYs due to time on LTBI treatment based on the amount of 
time on treatment (number of doses completed) at a rate of 0.03 lost QALYs per year on 
treatment, as described in the Model Inputs and Assumptions section.
Simulation
The program goes through one time step for each year of simulation. At each time step, the 
program does the following:
1. Each individual’s risk of progressing to TB disease during the current simulation 
year is calculated. For the first 3 years of simulation, as described in the Model 
Inputs and Assumptions section, this is the baseline risk set during the 
initialization phase based on clinical trial data. Thereafter, the TB risk for each 
individual declines by a factor of two each year to a minimum of 1/20 of the 
individual’s baseline value in approximation of the declining risk of TB disease 
observed among recent immigrants to the United States from high TB burden 
countries.2
2. Each individual’s risk of death during the current simulation year from causes 
unrelated to TB is set based on the individual’s current age using data from the 
2007 US Life Tables.36 Each individual undergoes a check for death from causes 
unrelated to TB or LTBI treatment; individuals who die enter the ‘dead’ state and 
accumulate no further costs or lost QALYs.
3. If it is the first year of simulation (i.e., the year during which individuals receive 
LTBI treatment), individuals undergo checks for drug toxicity (fatal toxicity, 
toxicity with hospitalization or toxicity without hospitalization) with the 
probabilities as described in the Model Inputs and Assumptions section above. 
Those experiencing toxicity have their individual toxicity-related costs and 
toxicity-related lost QALYs adjusted as described in the Model Inputs and 
Assumptions section. Individuals who die from toxicity lose one QALY for each 
lost year of life, where their expected future years of life are calculated based on 
the 2007 US Life Tables.36 As with all costs and health outcomes in the model 
(including QALYs, number of TB cases and number of deaths), the lost QALYs 
due toxicity-related death are discounted at annual rate of 3%, so that the value 
of 1 lost QALY in year k of simulation (where treatment occurs in year 0) is
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4. Individuals each undergo a check-up to see if they progress to TB disease during 
the current simulation year, with the risk of progression to TB disease as 
described above. Individuals who develop TB disease have their TB-related costs 
and QALYs lost updated as described in the Model Inputs and Assumptions 
section (discounted at an annual rate of 3%) and experience a one-time 5.8% 
chance of dying from TB disease. For those individuals who die from TB 
disease, the lost QALYs due to TB-related death are calculated in the same way 
as the lost QALYs due to toxicity-related death, as described above. Those 
individuals who develop TB disease lose 0.05 QALYs for each expected future 
year of life (discounted at an annual rate of 3%) based on the assumption that 
individuals have reduced quality of life for the duration of their lives after 
experiencing TB disease (see Model Inputs and Assumptions section). As with 
individuals who die from drug toxicity, the number of expected future years of 
life for each individual surviving TB disease is based on the 2007 US Life 
Tables.36 For each individual who develops TB, 0.46 additional cases are 
assumed to occur due to transmission. For the purpose of discounting (costs and 
number of TB cases), one third of these secondary cases are assumed to occur 
immediately in the current simulation year, a third are assumed to occur after 5 
more years and a third are assumed to occur after 25 years. That is, each primary 
case is assumed to lead to:
secondary cases, after discounting has been applied, where k is the current 
simulation year. Each secondary case is assumed to lead to costs and lost QALYs 
equal to those of an average TB case, discounted as above. The average cost of a 
TB case is taken to be:
The average QALY loss of a TB case is:
See the Model Inputs and Assumptions section for information on costs and 
QALY values.
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5. The year is incremented by one, and each individual’s age is incremented by one 
year.
6. The health system and societal costs to date for each individual are updated 
(individual cost = individual LTBI treatment cost + individual toxicity cost + 
individual cost of TB disease + costs arising from secondary TB cases). The 
QALYs lost to date are updated for each individual (individual QALYs lost = 
QALYs lost due to time on LTBI treatment + QALYs lost due to toxicity + 
QALYs lost due to TB disease + QALYs lost in secondary cases due to 
transmission). The current incremental cost per TB case prevented is calculated 
as:
Where 3HP denotes the set of all individuals receiving 3HP and 9H denotes the 
set of all individuals receiving 9H, ci is the discounted cumulative cost to 
individual i during the simulation so far, and di is the discounted number of TB 
cases (including secondary cases) involving individual i during the simulation so 
far. The current incremental cost per QALY gained by 3HP compared to 9H is 
calculated as:
where qi is the discounted cumulative QALYs lost by individual i so far in the 
simulation.
7. The next simulation time step begins.
8. The simulation runs for 20 simulated years (20 simulation time steps). At the end 
it reports the total costs, health outcomes, incremental cost per TB case 
prevented by 3HP compared to 9H, and incremental cost per QALY gained by 
3HP compared to 9H. Individual-level costs and health outcomes can also be 
queried after simulation.
9. The model was created and implemented using NetLogo version 5.0. NetLogo is 
free and publicly available, and can be downloaded from http://
ccl.northwestern.edu/netlogo/. The file containing the model source code can be 
downloaded from the authors of this report at http://www.mtholyoke.edu/
~dshepard/LTBI/LTBI-cost-effectiveness.zip. The model can be run (and 
modified) by users who download and install NetLogo.
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Sensitivity analysis
Univariate sensitivity analysis
The results of univariate sensitivity analyses, where model parameters were each varied 
independently while holding other parameters constant at their base case values, are 
presented in Table A.10 (an abbreviated version appears in Table 3 in the main article). The 
same random number generator seed was used for each sensitivity run to reduce the amount 
of variability in the results. Individual parameter sensitivity ranges (Table A.10) were chosen 
in an attempt to cover all reasonable values for each parameter.
Multivariate sensitivity analysis
In multivariate sensitivity analysis, groups of parameters were simultaneously varied from 
their base case values. For one representative multivariate sensitivity analysis, the input 
parameters varied, and the values taken by each parameter are presented in Table A.11. 
Assuming that each parameter can take on its base case value or one of its alternate values 
listed in Table A.11, there are 324 combinations of these parameter values. The results of 
this multivariate sensitivity analysis are presented in Figures A.2 and A.3, which show 
acceptability curves comparing the incremental cost per QALY gained by 3HP compared to 
9H from the health system (Figure A.2) and societal (Figure A.3) perspectives. The variable 
on the horizontal axis represents a threshold for the incremental cost per QALY gained by 
3HP compared to 9H, and the vertical axis gives the fraction of the 324 scenarios from this 
multivariate sensitivity analysis (Table A.11) for which the incremental cost per QALY 
gained falls below this threshold. For more information on acceptability curves in cost-
effectiveness analysis, see, for example, Briggs et al.38
Figure A.2. 
Health system perspective acceptability curve for the multivariate sensitivity analysis from 
Table A.11. Curve shows the fraction of sensitivity runs that were cost-effective from the 
health system perspective for each threshold value λ (the fraction of simulations for which 
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the incremental cost per QALY gained by 3HP compared to 9H was ≤λ). Each run 
represents one of the 324 combinations of parameters from Table A.11 and was simulated 
using 50 000 individuals for each regimen. QALY = quality-adjusted life years; 3HP = 12-
dose regimen of weekly rifapentine plus isoniazid; 9H = 9 months of daily, self-administered 
isoniazid.
From the health system perspective, 3HP was found to be cost-saving relative to 9H for 23% 
of the simulated scenarios from Table A.11 (i.e., the incremental cost per QALY gained by 
3HP compared to 9H was found to be negative for 23% of the simulations from Table A.11). 
For 50% of these simulations, the incremental cost per QALY gained by 3HP compared to 
9H was found to fall below a threshold of $6250. For 98% of the simulations, the 
incremental cost per QALY gained by 3HP compared to 9H was found to fall below a 
threshold of $50 000, a value often used as a threshold for cost-effectiveness of public health 
interventions in the United States in the past (Figure A.2).39
Figure A.3. 
Societal perspective acceptability curve for the multivariate sensitivity analysis from Table 
A.11. Curve shows the fraction of sensitivity runs that were cost-effective from the societal 
perspective for each threshold value λ (the fraction of simulations for which the incremental 
cost per QALY gained by 3HP compared to 9H was ≤λ). Each run represents one of the 324 
combinations of parameters from Table A.11 and was simulated using 50 000 individuals for 
each regimen. QALY = quality-adjusted life years; 3HP = 12-dose regimen of weekly 
rifapentine plus isoniazid; 9H = 9 months of daily, self-administered isoniazid.
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Table A.11
Parameters adjusted in one multivariate sensitivity analysis*
Input parameter
Parameter values explored
Base case value US
$ Alternative values US$
3HP medication cost per dose 12.31 5, 25
Directly observed therapy cost per dose 17.76 0, 35
TB hospitalization probability, % 49 25
Proportional change in risk of progression to tuberculosis disease, 
%
100 50, 150
Annual QALY loss from LTBI treatment 0.03 0
Cost of follow-up clinic visit 27.92 20, 35
*
Each parameter was assigned to each of the values given below (324 total simulations, one for each combination of 
parameters). All other parameter values were maintained at their base case levels. Each simulation included 50 000 
individuals for each regimen.
3HP = 12-dose regimen of weekly rifapentine plus isoniazid; QALY = quality-adjusted life years; LTBI = latent 
tuberculous infection.
From the societal perspective, 3HP was found to be cost-saving relative to 9H for 40% of the 
simulated scenarios from Table A.11. For 50% of these simulations, the incremental cost per 
QALY gained by 3HP compared to 9H was found to fall below a threshold of $2250. For 
99.7% of the simulations, the incremental cost per QALY gained by 3HP compared to 9H 
was found to fall below a threshold of $50000 (Figure A.3).
We undertook other multivariate sensitivity analyses similar to the one outlined in Table A.
11, where different input parameters and values were chosen for analysis. The results were 
broadly similar, i.e., our model predicts that the incremental cost per QALY gained by 3HP 
compared to 9H remains below $50 000 from both the health system and societal 
perspectives over a wide range of input parameter values.
Scenario sensitivity analysis
In addition to the sensitivity analyses described above, several specific scenarios were 
explored. In the clinical trial, after adjustment for HIV infection, smoking, and low body 
mass index patients receiving 3HP were found to be at lower risk for TB than patients 
receiving 9H, with the rate of TB in the 3HP population approximately half that in the 9H 
population, and our base case analysis assumes this is the case. The clinical trial 
investigators concluded that 3HP is at least as effective as 9H.1 In sensitivity analysis, we 
tested the case that 3HP and 9H are equivalent in two different ways:
1. The baseline TB risk for simulated individuals completing nine or more 3HP 
doses was set to the same level as the TB risk for those completing 241 or more 
9H doses (i.e., the annual risk of progression to TB disease for simulated 
individuals taking nine or more doses of 3HP was raised from the base case 
value of 0.05% to 0.08%). Under this scenario, 3HP and 9H are assumed to be 
equally effective for patients who complete treatment, but 3HP retains an 
advantage due to greater adherence. In this case, the average number of TB cases 
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per 1000 LTBI treatment starts rises from 3.9 to 5.1 for individuals receiving 
3HP, and the cost per individual treated increases from $623 to $644 (health 
system) or from $728 to $751 (societal). The incremental cost per TB case 
prevented by 3HP compared to 9H increases from $21 525 to $38 775 (health 
system) or from $4294 to $13 223 (societal), and the incremental cost per QALY 
gained by 3HP compared to 9H rises from $4565 to $6361 (health system) or 
from $911 to $2169 (societal).
2. The baseline TB risk for all simulated individuals receiving 3HP and 9H was set 
to the level observed in the modified intention-to-treat population in the clinical 
trial (i.e., all individuals starting LTBI treatment had a baseline annual risk of 
progression to TB disease of 0.16%).1 In this case, 3HP and 9H are assumed to 
be equivalent in terms of their effectiveness in preventing TB. As both 
populations experience the same average number of TB cases, the cost per TB 
case prevented is not a valid measure of cost-effectiveness under this scenario. 
The average cost per person treated increases from the base case value of $623 to 
$710 (health system) or from $728 to $825 (societal), and the incremental cost 
per QALY gained by 3HP compared to 9H rises from $4565 to $14 292 (health 
system) or from $911 to $8559 (societal) with the difference in QALYs between 
the regimens due entirely to the different durations of LTBI treatment and risks 
of drug toxicity.
The gains in QALYs from 3HP are due in part to the assumptions that individuals on LTBI 
treatment experience reduced quality of life (0.03 lost QALY per year) for the duration of 
treatment and patients with previous active TB experience reduced quality of life (0.05 lost 
QALY per year) for their remaining years of life.25 When individuals are assumed to 
experience no loss in quality of life due to LTBI treatment or due to previous active TB, as in 
a recent cost-effectiveness analysis of screening strategies for LTBI,33 the cost per QALY 
gained for 3HP vs. 9H increases to $17 186 (health system) or $3429 (societal).
Due to computational limitations and the number of parameters involved, an exhaustive 
exploration of the space of possible parameter values is not possible. Readers who would 
like to explore other combinations of alternative input parameter values are encouraged to 
download the NetLogo source code for the simulation model which will allow them to set 
the input parameters to their desired values and conduct their own analyses using our 
simulation model.
Analysis of stochastic variability
Because of the stochastic nature of the individual-based model created here, there is 
randomness built into the model results. We analysed the stochastic variability in model 
results by using bootstrap re-sampling.40 Simulation data were used to populate 1000 
different sets of 100 000 individuals for each regimen by resampling with replacement from 
the original simulation population of 100 000 individuals for each regimen. For each set of 
individuals created by bootstrap resampling, the number of TB cases and QALYs lost, as 
well as the mean health system and societal costs, were computed for each regimen. The 
health system and societal costs per TB case prevented and per QALY gained by 3HP 
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compared to 9H were also calculated for each population created by bootstrap resampling. 
The distributions of these measures in the 1000 hypothetical populations created by 
bootstrap resampling of simulation data were used to estimate the 2.5 and 97.5 centiles and 
the 95% confidence interval for each measure.
Model availability
Interested users should first download and install NetLogo from http://ccl.northwestern.edu/
netlogo/. Our simulation model is available from http://www.mtholyoke.edu/~dshepard/
LTBI-cost-effectiveness.zip. Many model parameters (analytic horizon, price of RTP, 
secondary transmission rate, adherence rates for 3HP and 9H, and many others) can be 
modified through the model’s graphic user interface; other model parameters and the model 
structure can be modified by editing the source code (also provided) directly. Our hope is 
that by making the model publicly available, we will enable interested users to modify it to 
better suit local conditions.
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Figure 1. 
Cost of a complete course of treatment for latent tuberculous infection with either 9H or 
3HP administered by DOT from a health care worker. Patients receiving 9H have an initial 
clinic visit and eight later clinic visits; those receiving 3HP have an initial clinic visit, two 
later clinic visits and 12 visits by a health care worker for DOT. Patient costs include out-of-
pocket expenses and lost productivity; other costs are costs to the health system. Costs are in 
2010 US dollars. 3HP = 3 months of weekly isoniazid plus rifapentine; 9H = 9 months of 
daily, self-administered isoniazid; DOT = directly observed treatment.
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Figure 2. 
Total costs per person treated for LTBI. Average costs are over a 20-year period for 
individuals treated for LTBI with either 9H or 3HP administered by DOT from a health care 
worker. Costs include those of LTBI treatment and the eventual development of tuberculosis 
disease in some individuals. Patient costs include out-of-pocket expenses and lost 
productivity; other costs are costs to the health system. Based on 100 000 simulated 
individuals per regimen with a 20-year analytic horizon; costs are reported in 2010 US 
dollars and have been discounted at an annual rate of 3%. LTBI = latent tuberculous 
infection; 3HP = 3 months of weekly isoniazid plus rifapentine; 9H = 9 months of daily, 
self-administered isoniazid; DOT = directly observed treatment.
Shepardson et al. Page 37
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2017 May 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Shepardson et al. Page 38
Table 1
Inputs for a cost-effectiveness model comparing 3HP with direct observation by a health care worker to 9H for 
treatment of LTBI; values are those used in the base case analysis
Cost Societal cost US$ Health system cost US$ Source/reference*
LTBI treatment
 Cost of initial visit (excluding medicines) 203 166 Nashville Public Health Department
 Cost per follow-up visit (excluding medicines) 50 28 Nashville Public Health Department
 DOT, cost per dose 20 18 Nashville Public Health Department
 Cost per dose, 9H 0.05 0.05 Department of Veterans Affairs
 Cost per dose, 3HP 12.31 12.31 Department of Veterans Affairs
LTBI drug toxicity 8, 9
 Toxicity without hospitalization 169 169
 Toxicity with hospitalization 6 650 5 677
Active TB
 Diagnostic costs 298 259 9–11
 Out-patient treatment 2 958 2 725
 Hospitalization (if required) 28 831 25 495
Quality of life adjustments QALY lost per year 8
Health state
 LTBI treatment 0.03
 Drug toxicity 0.25
 Hospitalization 0.50
 Treatment of active TB 0.10
 Previous active TB 0.05
Baseline TB risk, years 1–3 after treatment start % of patients
Annual risk of 
progression to TB %
9H doses taken Tuberculosis Trials Consortium Data 
Management Center
 0–90 17 0.36
 91–240 15 0.28
 241+ 68 0.08
3HP doses taken Tuberculosis Trials Consortium Data 
Management Center
 0–8 16 0.13
 9+ 84 0.05
LTBI drug toxicity, probabilities per treatment start 9H 3HP
Probability of drug toxicity 5.5 8.2 3
Probability of hospitalization from toxicity 0.1 0.3 3
Probability of death from drug toxicity 0.014 0.014 12, 13
Other Value
Age at LTBI treatment start Distribution 3
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Cost Societal cost US$ Health system cost US$ Source/reference*
Probability of death from TB 5.8% Tuberculosis Epidemiologic Studies 
Consortium, CDC
Background mortality rate Age-dependent 14
Patient time valuation (2010 US$)
 Hourly (clinic visits) $12.73 15
 Daily (overnight hospitalization) $139.00 16
Probability of hospitalization for TB 0.49 9
Secondary TB cases per primary case 0.46 17–20
*Unreferenced sources refer to unpublished data; see Acknowledgements.
3HP = 3 months of weekly isoniazid plus rifapentine; 9H = 9 months of daily, self-administered isoniazid; LTBI = latent tuberculous infection; 
DOT = directly observed treatment; TB = tuberculosis; CDC = Centers for Disease Control and Prevention.
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Table 3
Results of univariate sensitivity analysis for cost per TB case prevented and cost per QALY gained comparing 
3HP to 9H*
Parameter
Health system perspective Societal perspective
Incremental cost/TB 
case prevented Incremental cost/QALY gained
Incremental cost/TB 
case prevented Incremental cost/QALY gained
DOT cost/dose ($17.76)
 $0 <0 <0 <0 <0
 $35 56124 11902 38893 8248
3HP medication cost per dose ($12.31)
 $5 6 854 1 454 <0 <0
 $25 46992 9965 29762 6311
 $35 67061 14221 39796 8439
TB hospitalization probability (49%)
 0% 32855 6983 17188 3653
 75% 15140 3207 <0 <0
Proportional change in risk of progression to TB disease (100%)
 50% 47861 7163 19007 2845
 150% 8 002 2 001 <0 <0
 200% 1 941 594 <0 <0
Patient hourly time value ($12.73)
 $0 21525 4565 18669 3959
 $7.50 21525 4565 10200 2163
 $17.00 21525 4565 <0 <0
Secondary TB cases per primary case (0.46)
 0 34895 6436 12153 2242
 0.6 18753 4104 2665 583
9H completion proportion (68%)
 63% 14906 3248 1145 250
 57% 15170 3464 2648 605
 51% 11378 3183 1043 292
3HP completion proportion (83%)
 76% 16969 3209 <0 <0
 69% 19259 3922 <0 <0
 62% 15220 2518 <0 <0
3HP toxicity probability (8.2%)
 3% 16629 3749 <0 <0
 13% 25458 5158 7686 1557
Probability of death from TB disease (5.8%)
 2% 21332 5655 3828 1015
 15% 21424 3856 3862 695
Cost of hospitalization for TB ($25 495)
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Parameter
Health system perspective Societal perspective
Incremental cost/TB 
case prevented Incremental cost/QALY gained
Incremental cost/TB 
case prevented Incremental cost/QALY gained
 $10000 28411 6025 11181 2371
 $40000 15078 3197 <0 <0
*
Base case values are reported in parentheses. Entries with values <0 (where the incremental cost-effectiveness ratios are negative) represent 
scenarios where 3HP is cost-saving compared to 9H. Simulation run for each set of parameter values with 100 000 simulated individuals for each 
regimen, with an analytic horizon of 20 years. All costs and health outcomes have been discounted at an annual rate of 3%. Costs are in 2010 US 
dollars. An expanded version of this table appears in the Appendix.
TB = tuberculosis; QALY = quality-adjusted life year; 3HP = 3 months of weekly isoniazid plus rifapentine; 9H = 9 months of daily, self-
administered isoniazid; DOT = directly observed treatment.
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